UBM aligns CMP's US, European units

Share this article:
CMP Healthcare parent United Business Media consolidated its global healthcare operations into CMPMedica, aligning its US healthcare businesses like the Cliggott and Oncology Group journals with their European and Asian counterparts.

The new regime, which breaks CMP into separate medical and technology units, won't mean much of a change for the firm's US operations, said Vicki Masseria, president.

“UBM has pooled the healthcare assets of CMP so that we're one global brand now,” said Masseria, who will report to new CEO of CMPMedica Henry Elkington, who previously headed business development for the firm. Steve Weitzner, previously president and CEO of CMP, will now head CMP Technology.

The realignment brings together the company's US publishing and medical education business with a strong European drug information business, based in France.

“We all have different skill sets. Uniting all of our healthcare assets brings together global expertise in print, events, online, et cetera,” said Masseria.

CMPMedica's US titles include Oncology, Psychiatric Times, Applied Neurology, Consultant, Drug Benefit Trends and The Journal of Respiratory Diseases. The firm's French drug information business includes the Vidal Pharmaceutical Directory, and the healthcare business of CMPi, the company's European integrated marketing and professional media division, has been integrated into CMPMedica.

UBM clocked CMPMedica's pro forma 2005 revenues at about £170 million, or $313 million. By contrast, the CMP Technology business was worth £200 million, or $369 million.

Elkington was most recently director of corporate development at UBM, having joined the firm last August. He had previously spent 16 years at Boston Consulting Group, where he advised on strategy, mergers and acquisitions and post-merger integration in industries including pharmaceuticals, media and telecoms.

Share this article:
You must be a registered member of MMM to post a comment.

Next Article in News

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.